| ［1］ |
Hanna S, Etzioni A, Etzoni A. New host defense mechanisms against Candida species clarify the basis of clinical phenotypes［J］. J Allergy Clin Immunol, 2011, 127（6）: 1433⁃1437. DOI: 10. 1016/j.jaci.2011.03.026.
|
| ［2］ |
Sparber F, LeibundGut⁃Landmann S. Interleukin 17⁃mediated host defense against Candida albicans［J］. Pathogens, 2015, 4（3）: 606⁃619. DOI: 10.3390/pathogens4030606.
|
| ［3］ |
Puel A, Cypowyj S, Maródi L, et al. Inborn errors of human IL⁃17 immunity underlie chronic mucocutaneous candidiasis［J］. Curr Opin Allergy Clin Immunol, 2012, 12（6）: 616⁃622. DOI: 10.1097/ ACI.0b013e328358cc0b.
|
| ［4］ |
Puel A, Döffinger R, Natividad A, et al. Autoantibodies against IL⁃17A, IL⁃17F, and IL⁃22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I［J］. J Exp Med, 2010, 207（2）: 291⁃297. DOI: 10.1084/jem.20091983.
|
| ［5］ |
Delsing CE, Bleeker⁃Rovers CP, Kullberg BJ, et al. Treatment of candidiasis: insights from host genetics［J］. Expert Rev Anti Infect Ther, 2012, 10（8）: 947⁃956. DOI: 10.1586/eri.12.79.
|
| ［6］ |
Bishu S, Hernández⁃Santos N, Simpson⁃Abelson MR, et al. The adaptor CARD9 is required for adaptive but not innate immunity to oral mucosal Candida albicans infections［J］. Infect Immun, 2014, 82（3）: 1173⁃1180. DOI: 10.1128/IAI.01335⁃13.
|
| ［7］ |
Drummond RA, Saijo S, Iwakura Y, et al. The role of Syk/CARD9 coupled C⁃type lectins in antifungal immunity［J］. Eur J Immunol, 2011, 41（2）: 276⁃281. DOI: 10.1002/eji.201041252.
|
| ［8］ |
Bär E, Gladiator A, Bastidas S, et al. A novel Th cell epitope of Candida albicans mediates protection from fungal infection［J］. J Immunol, 2012, 188（11）: 5636⁃5643. DOI: 10.4049/jimmunol. 1200594.
|
| ［9］ |
Aydin SE, Kilic SS , Aytekin C, et al. DOCK8 deficiency: clinical and immunological phenotype and treatment options—a review of 136 patients［J］. J Clin Immunol, 2015, 35（2）: 189⁃198. DOI: 10.1007/s10875⁃014⁃0126⁃0.
|
| ［10］ |
Kisand K, Bøe Wolff AS, Podkrajsek KT, et al. Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17⁃associated cytokines［J］. J Exp Med, 2010, 207（2）: 299⁃308. DOI: 10.1084/jem.20091669.
|
| ［11］ |
Pedroza LA, Kumar V, Sanborn KB, et al. Autoimmune regulator （AIRE） contributes to Dectin⁃1⁃induced TNF⁃α production and complexes with caspase recruitment domain⁃containing protein 9 （CARD9）, spleen tyrosine kinase （Syk）, and Dectin⁃1［J］. J Allergy Clin Immunol, 2012, 129（2）: 464⁃472, 472.e1⁃3. DOI: 10.1016/j.jaci.2011.08.027.
|
| ［12］ |
Okadas S, Markle JG, Deenick EK, et al. Impairment of immunity to Candida and Mykobacterium in humans with bi⁃allelic RORC mutations［J］. Science, 2015, 349（6248）: 603⁃613. DOI: 10.1126/science.aaa4282.
|
| ［13］ |
de Diego R P, Sánchez⁃Ramón S, López⁃Collazo E, et al. Genetic errors of the human caspase recruitment domain⁃B⁃cell lymphoma 10⁃mucosa⁃associated lymphoid tissue lymphoma⁃translocation gene 1 （CBM） complex: molecular, immunologic, and clinical heterogeneity［J］. J Allergy Clin Immunol, 2015, 136（5）: 1139⁃1149. DOI: 10.1016/j.jaci.2015.06.031.
|
| ［14］ |
Glocker EO, Hennigs A, Nabavi M, et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections［J］. N Engl J Med, 2009, 361（18）: 1727⁃1735. DOI: 10.1056/NEJMoa0810719.
|
| ［15］ |
Liu L, Okada S, Kong XF, et al. Gain⁃of⁃function human STAT1 mutations impair IL⁃17 immunity and underlie chronic mucocuta⁃neous candidiasis［J］. J Exp Med, 2011, 208（8）: 1635⁃1648. DOI: 10.1084/jem.20110958.
|
| ［16］ |
van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candi⁃diasis［J］. N Engl J Med, 2011, 365（1）: 54⁃61. DOI: 10.1056/NEJMoa1100102.
|
| ［17］ |
Takezaki S, Yamada M, Kato M, et al. Chronic mucocutaneous candidiasis caused by a gain⁃of⁃function mutation in the STAT1 DNA⁃binding domain［J］. J Immunol, 2012, 189（3）: 1521⁃1526. DOI: 10.4049/jimmunol.1200926.
|
| ［18］ |
Sobh A, Chou J, Schneider L, et al. Chronic mucocutaneous candidiasis associated with an SH2 domain gain⁃of⁃function mutation that enhances STAT1 phosphorylation［J］. J Allergy Clin Immunol, 2016, 138（1）: 297⁃299. DOI: 10.1016/j.jaci.2015.12. 1320.
|
| ［19］ |
Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin⁃17 immunity［J］. Science, 2011, 332（6025）: 65⁃68. DOI: 10.1126/science.1200439.
|
| ［20］ |
Ling Y, Cypowyj S, Aytekin C, et al. Inherited IL⁃17RC deficiency in patients with chronic mucocutaneous candidiasis［J］. J Exp Med, 2015, 212（5）: 619⁃631. DOI: 10.1084/jem.20141065.
|
| ［21］ |
Boisson B, Wang C, Pedergnana V, et al. An ACT1 mutation selectively abolishes interleukin⁃17 responses in humans with chronic mucocutaneous candidiasis［J］. Immunity, 2013, 39（4）: 676⁃686. DOI: 10.1016/j.immuni.2013.09.002.
|
| ［22］ |
Nahum A, Dadi H, Bates A, et al. The biological significance of TLR3 variant, L412F, in conferring susceptibility to cutaneous candidiasis, CMV and autoimmunity［J］. Autoimmun Rev, 2012, 11（5）: 341⁃347. DOI: 10.1016/j.autrev.2011.10.007.
|
